New Zealand markets closed

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
344.91-12.57 (-3.52%)
As of 03:09PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close357.48
Open360.56
Bid346.36 x 800
Ask346.56 x 1200
Day's range341.03 - 362.49
52-week range335.68 - 555.77
Volume733,047
Avg. volume852,895
Market cap53.937B
Beta (5Y monthly)0.86
PE ratio (TTM)56.46
EPS (TTM)6.11
Earnings date09 Feb 2022 - 14 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est437.13
  • Bloomberg

    GIFs Were the Last Straw: Facebook Gets First Order to Unwind Completed Deal

    (Bloomberg) -- Few would have predicted that short video loops of Kanye West or cats furiously typing on laptops would be the final straw for competition regulators.Most Read from Bloomberg‘Ghost Signs’ Haunt London’s Reviving NeighborhoodsReliving the New York Subway Map DebateThe Hot New Trend For Hedge Funds Is—Finally—Female FoundersAutomating the War on Noise PollutionChina Cash Flowed Through Congo Bank to Former President’s CroniesYet on Tuesday, the U.K. ordered Meta Inc.’s Facebook to s

  • Bloomberg

    Facebook Owner Meta Must Sell Giphy on Competition Concerns, U.K. Says

    (Bloomberg) -- Britain’s antitrust watchdog ordered Facebook parent Meta Platforms Inc. to sell Giphy, the first time a global regulator has forced a Big Tech firm to unwind a completed deal. A turnaround after years of being allowed to swallow up smaller rivals with virtually no push back.Most Read from Bloomberg‘Ghost Signs’ Haunt London’s Reviving NeighborhoodsReliving the New York Subway Map DebateAutomating the War on Noise PollutionThe Hot New Trend For Hedge Funds Is—Finally—Female Founde

  • Motley Fool

    10x Genomics Stock: Bull vs. Bear

    Despite crushing the S&P 500 -- 180% to 63% -- since its September 2019 IPO, 10x Genomics' (NASDAQ: TXG) shares have only experienced 6% growth year to date. The company has rapidly become a cornerstone of biomedical research with its laboratory devices capable of profiling individual cells, but investors recently seem to have shrugged. Does the stock price just need a few quarters to catch up to its valuation?